Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PPHM
  • CUSIP: N/A
  • Web: www.peregrineinc.com
Capitalization:
  • Market Cap: $186.25 million
  • Outstanding Shares: 45,096,000
Average Prices:
  • 50 Day Moving Avg: $3.31
  • 200 Day Moving Avg: $3.89
  • 52 Week Range: $1.96 - $5.78
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $79.1 million
  • Price / Sales: 2.33
  • Book Value: $1.24 per share
  • Price / Book: 3.29
Profitability:
  • EBITDA: ($17,420,000.00)
  • Net Margins: -23.15%
  • Return on Equity: -38.19%
  • Return on Assets: -16.66%
Debt:
  • Current Ratio: 1.67%
  • Quick Ratio: 1.10%
Misc:
  • Average Volume: 238,878 shs.
  • Beta: 2.56
  • Short Ratio: 1.95
 

Frequently Asked Questions for Peregrine Pharmaceuticals (NASDAQ:PPHM)

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Shares of Peregrine Pharmaceuticals reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) posted its earnings results on Monday, September, 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.06. The business had revenue of $27.08 million for the quarter, compared to analysts' expectations of $15.22 million. Peregrine Pharmaceuticals had a negative net margin of 23.15% and a negative return on equity of 38.19%. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, December, 11th 2017. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued 12-month price targets for Peregrine Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Peregrine Pharmaceuticals' share price to reach $10.00 in the next year. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Carlton M. Johnson Jr., Independent Chairman of the Board
  • Steven W. King, President, Chief Executive Officer, Director
  • Paul J. Lytle, Chief Financial Officer
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs
  • David H. Pohl, Independent Director
  • Eric S. Swartz, Independent Director

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%) and Eqis Capital Management Inc. (0.32%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who sold Peregrine Pharmaceuticals stock? Who is selling Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $4.08.


MarketBeat Community Rating for Peregrine Pharmaceuticals (NASDAQ PPHM)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (145.10% upside)
Consensus Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/29/2017Noble FinancialInitiated CoverageBuy -> Buy$10.00LowView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings History by Quarter for Peregrine Pharmaceuticals (NASDAQ PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/11/2017        
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Source:
DateHeadline
streetinsider.com logoPeregrine Pharma (PPHM) Appoints Mark Bamforth to Board - StreetInsider.com
www.streetinsider.com - October 19 at 3:33 PM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices
finance.yahoo.com - October 19 at 3:33 PM
americanbankingnews.com logoContrasting Kadmon Holdings (KDMN) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 18 at 8:20 PM
americanbankingnews.com logoCritical Contrast: Peregrine Pharmaceuticals (PPHM) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 18 at 4:24 PM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 12, 2017
finance.yahoo.com - October 13 at 8:14 AM
prnewswire.com logoRonin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals - PR Newswire (press release)
www.prnewswire.com - October 11 at 6:40 AM
finance.yahoo.com logoRonin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals
finance.yahoo.com - October 11 at 6:40 AM
americanbankingnews.com logoReviewing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - October 8 at 2:24 PM
finance.yahoo.com logoEarnings Review and Free Research Report: Peregrine Pharma’s Q1 Top-line Surged 383% Y-o-Y; Beat Projections
finance.yahoo.com - October 5 at 5:16 PM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Now Covered by Noble Financial
www.americanbankingnews.com - September 29 at 6:00 PM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 7:10 PM
globenewswire.com logoAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius ... - GlobeNewswire (press release)
globenewswire.com - September 25 at 5:16 PM
finance.yahoo.com logoAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford Facility
finance.yahoo.com - September 25 at 12:09 PM
seekingalpha.com logoUn-Spinning The Peregrine Pharmaceuticals Spin Zone - Seeking Alpha
seekingalpha.com - September 22 at 7:01 PM
americanbankingnews.com logoComparing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - September 21 at 4:26 PM
globenewswire.com logoAvid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition - GlobeNewswire (press release)
globenewswire.com - September 20 at 7:55 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 Results
finance.yahoo.com - September 20 at 7:55 AM
americanbankingnews.com logoHead to Head Review: Peregrine Pharmaceuticals (PPHM) versus Its Peers
www.americanbankingnews.com - September 15 at 4:28 PM
seekingalpha.com logoPeregrine's Well Is Running Dry - Seeking Alpha
seekingalpha.com - September 15 at 7:44 AM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 7:44 AM
americanbankingnews.com logoHead to Head Contrast: Peregrine Pharmaceuticals (PPHM) & Its Competitors
www.americanbankingnews.com - September 15 at 4:32 AM
finance.yahoo.com logoPeregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 9:21 AM
thestreet.com logoStock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet
www.thestreet.com - September 12 at 8:46 AM
seekingalpha.com logoYour Weekly Pharma Scoop: Valeant's CRL Resolution, Eagle Undervalued, Array Positive Results
seekingalpha.com - September 12 at 8:46 AM
rttnews.com logoKeep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted
www.rttnews.com - September 12 at 8:46 AM
finance.yahoo.com logoInvestor Network: Peregrine Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - September 12 at 8:46 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments
finance.yahoo.com - September 12 at 8:46 AM
finance.yahoo.com logoEdited Transcript of PPHM earnings conference call or presentation 11-Sep-17 8:30pm GMT
finance.yahoo.com - September 12 at 8:46 AM
finance.yahoo.com logoPeregrine reports 1Q loss
finance.yahoo.com - September 12 at 8:46 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - September 11 at 8:20 PM
americanbankingnews.com logoReviewing Transition Therapeutics (TTHI) & Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - September 11 at 12:08 AM
globenewswire.com logoPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment ... - GlobeNewswire (press release)
globenewswire.com - September 9 at 7:32 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
finance.yahoo.com - September 8 at 7:15 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - September 7 at 10:24 AM
finance.yahoo.com logoPeregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017
finance.yahoo.com - September 7 at 7:47 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 6:28 AM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - August 31 at 8:53 AM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - August 31 at 8:53 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - August 30 at 8:07 AM
globenewswire.com logoAvid Bioservices to Exhibit at The Bioprocessing Summit 2017 - GlobeNewswire (press release)
globenewswire.com - August 17 at 6:58 AM
globenewswire.com logoAvid Bioservices to Exhibit at The Bioprocessing Summit 2017 - GlobeNewswire (press release)
globenewswire.com - August 17 at 6:58 AM
prnewswire.com logoRonin Trading and SW Investment Management Respond to Recent Announcements by Peregrine Pharmaceuticals - PR Newswire (press release)
www.prnewswire.com - August 15 at 6:20 AM
finance.yahoo.com logoRonin Trading and SW Investment Management Respond to Recent Announcements by Peregrine Pharmaceuticals
finance.yahoo.com - August 15 at 6:20 AM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 6:20 AM
rttnews.com logoPeregrine Pharma Cuts Jobs
www.rttnews.com - August 13 at 3:47 AM
streetinsider.com logoPeregrine Pharma (PPHM) to Reduce Workforce by 20% as Part of Planned Strategic Actions to Reduce Costs
www.streetinsider.com - August 13 at 3:47 AM
marketwatch.com logoPeregrine Pharmaceuticals laid off one-fifth of its workforce - MarketWatch
www.marketwatch.com - August 12 at 7:00 AM
seekingalpha.com logoPeregrine Pharma retools operations, 60 jobs axed - Seeking Alpha
seekingalpha.com - August 12 at 7:00 AM
finance.yahoo.com logoPeregrine Pharmaceuticals laid off one-fifth of its workforce
finance.yahoo.com - August 12 at 6:59 AM
americanbankingnews.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 3:02 PM

Social

Chart

Peregrine Pharmaceuticals (PPHM) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.